Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

1. Taxonera, C.
2. Iborra, M.
3. Bosca-Watts, M.M.
4. Rubio, S.
5. Nantes, Ó.
6. Higuera, R.
7. Bertoletti, F.
8. Martínez-Montiel, P.
9. Sierra-Ausin, M.
10. Manceñido, N.
11. Lázaro Pérez-Calle, J.
12. Algaba, A.
13. Olivares, D.
14. Alba, C.